vTv Therapeutics Inc. (NASDAQ:VTVT) finished Wednesday with an addition of $0.04 to close at $0.71, an upside of 5.41 percent. An average of 1,000,114 shares of common stock have been traded in the last five days. There was a gain of $0.0120 in the past week, and it reached a new high 3 times over the past 12 months. The last 20 days have seen an average of 321,908 shares traded, while the 50-day average volume stands at 229,783.
VTVT stock has decreased by -5.66% in the last month. The company shares reached their 1-month lowest point of $0.6315 on 08/01/23. With the stock rallying to its 52-week high on 01/23/23, shares of the company touched a low of $0.63 and a high of $1.40 in 52 weeks. It has reached a new high 10 times so far this year and achieved 6.74% or $0.0652 in price. In spite of this, the price is down -49.46% from the 52-week high.
Valuation Metrics
vTv Therapeutics Inc. (VTVT) stock’s beta is -1.16. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 4111.75.
Financial Health
The quick ratio of vTv Therapeutics Inc. for the three months ended March 30 was 2.40, and the current ratio was 2.40, indicating that the company is able to meet its debt obligations. vTv Therapeutics Inc.’s EBITDA margin for the year ending March 30 is -1112.39%. Its gross profit as reported stood at $24.56 million compared to revenue of $2.02 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, vTv Therapeutics Inc.’s return on assets was -49.50%.
Earnings Surprise
For the three-month period that ended March 30, vTv Therapeutics Inc. had $20000.0 in cash. The company posted a net income of -$4.5 million in the quarter, while revenues of -$4.75 million were shrunk -55.78%. The analyst consensus anticipated vTv Therapeutics Inc.’s latest quarter earnings to come in at -$0.09 per share, but it turned out to be -$0.06, a 33.30% surprise. For the quarter, EBITDA amounted to -$7.41 million. Shareholders own equity worth $104.58 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at vTv Therapeutics Inc. (VTVT) price momentum. RSI 9-day as of the close on 09 August was 56.65%, suggesting the stock is Neutral, with historical volatility in this time frame at 67.79%.
As of today, VTVT’s price is $0.7002 +1.68% or $0.0120 from its 5-day moving average. VTVT is currently trading -1.62% lower than its 20-day SMA and -6.22% lower than its 100-day SMA. However, the stock’s current price level is -9.73% below the SMA50 and -9.25% below the SMA200.
The stochastic %K and %D were 50.36% and 54.69%, respectively, and the average true range (ATR) was 0.0473. With the 14-day stochastic at 64.98% and the average true range at 0.0448, the RSI (14) stands at 52.63%. The stock has reached -0.0120 on the 9-day MACD Oscillator while the 14-day reading was at 0.0003.
Analyst Ratings
H.C. Wainwright launched coverage on vTv Therapeutics Inc. (NASDAQ: VTVT) in its analyst report released on May 30, 2019. The firm assigned the stock a Buy rating. The consensus rating for vTv Therapeutics Inc. (VTVT) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell VTVT, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 1 others rate it as a “buy”.
What is VTVT’s price target for the next 12 months?
Analysts predict a range of price targets between $4.00 and $4.00, with a median target of $4.00. Taking a look at these predictions, the average price target given by analysts for vTv Therapeutics Inc. (VTVT) stock is $4.00.
